PURPOSE: The objective of this study was to determine the fate of the 166Ho-chitosan complex (DW-166HC) in rats by examining its absorption, distribution and excretion after administration into the prostate. METHODS: About 100 microCi of DW-166HC [containing 0.1875 mg of Ho(NO3)3.5H2O and 0.25 mg of chitosan] was administered intraprostatically. The level of radioactivity in blood, urinary and faecal excretion, and radioactivity distribution were examined. To determine the effect of chitosan in DW-166HC, 166Ho nitrate alone [0.1875 mg of Ho(NO3)3.5H2O] was administered into the prostate of male rats, and radioactivity distribution was examined using whole-body autoradiography. RESULTS: After administration of DW-166HC into the prostate, cumulative urinary and faecal excretion over the period 0-72 h was 0.35% and 0.11%, respectively. The radioactivity at the administration site was extremely high at all time points up to 144 h (>98% of injected dose). The small amount of radioactivity which did transfer from the administration site distributed mainly to the liver, spleen, kidney cortex and bone. Compared with the DW-166HC group, the group that received 166Ho nitrate alone displayed three- to fourfold higher levels of radioactivity in the main tissues, including liver, spleen, kidney cortex and bone, at 24 h after administration (P < 0.05). CONCLUSION: The results of this study show clearly that most of the administered DW-166HC remained at the administration site. It is concluded that the chitosan complex may be used to retain 166Ho within a limited area in cancer of the prostate.
PURPOSE: The objective of this study was to determine the fate of the 166Ho-chitosan complex (DW-166HC) in rats by examining its absorption, distribution and excretion after administration into the prostate. METHODS: About 100 microCi of DW-166HC [containing 0.1875 mg of Ho(NO3)3.5H2O and 0.25 mg of chitosan] was administered intraprostatically. The level of radioactivity in blood, urinary and faecal excretion, and radioactivity distribution were examined. To determine the effect of chitosan in DW-166HC, 166Ho nitrate alone [0.1875 mg of Ho(NO3)3.5H2O] was administered into the prostate of male rats, and radioactivity distribution was examined using whole-body autoradiography. RESULTS: After administration of DW-166HC into the prostate, cumulative urinary and faecal excretion over the period 0-72 h was 0.35% and 0.11%, respectively. The radioactivity at the administration site was extremely high at all time points up to 144 h (>98% of injected dose). The small amount of radioactivity which did transfer from the administration site distributed mainly to the liver, spleen, kidney cortex and bone. Compared with the DW-166HC group, the group that received 166Ho nitrate alone displayed three- to fourfold higher levels of radioactivity in the main tissues, including liver, spleen, kidney cortex and bone, at 24 h after administration (P < 0.05). CONCLUSION: The results of this study show clearly that most of the administered DW-166HC remained at the administration site. It is concluded that the chitosan complex may be used to retain 166Ho within a limited area in cancer of the prostate.
Authors: N K Cheung; B Landmeier; J Neely; A D Nelson; C Abramowsky; S Ellery; R B Adams; F Miraldi Journal: J Natl Cancer Inst Date: 1986-09 Impact factor: 13.506
Authors: J L Young; C L Percy; A J Asire; J W Berg; M M Cusano; L A Gloeckler; J W Horm; W I Lourie; E S Pollack; E M Shambaugh Journal: Natl Cancer Inst Monogr Date: 1981-06
Authors: S Kinuya; J M Jeong; K Garmestani; T Saga; L Camera; M W Brechbiel; O A Gansow; J A Carrasquillo; R D Neumann; C H Paik Journal: J Nucl Med Date: 1994-11 Impact factor: 10.057
Authors: B G Beatty; R J Paxton; M F Hawthorne; L E Williams; K J Rickard-Dickson; T Do; J E Shively; J D Beatty Journal: J Nucl Med Date: 1993-08 Impact factor: 10.057
Authors: S J Wang; W Y Lin; M N Chen; C S Chi; J T Chen; W L Ho; B T Hsieh; L H Shen; Z T Tsai; G Ting; S Mirzadeh; F F Knapp Journal: J Nucl Med Date: 1998-10 Impact factor: 10.057
Authors: Cheol Kwak; Sung Kyu Hong; Seung Kyoo Seong; Jei Man Ryu; Moon Soo Park; Sang Eun Lee Journal: Eur J Nucl Med Mol Imaging Date: 2005-08-31 Impact factor: 9.236